Evonik expands global production of hydroxyl‑terminated polybutadienes
Evonik is reinforcing its growth strategy by further strengthening its global production infrastructure for hydroxyl-terminated polybutadienes (HTPB). ... MORE
Evonik is reinforcing its growth strategy by further strengthening its global production infrastructure for hydroxyl-terminated polybutadienes (HTPB). ... MORE
The Executive Board discussed Evonik's dividend policy based on the preliminary results for 2025 and the outlook for 2026. As reported in an ad hoc announcement earlier today, Evonik targets an annual shareholder distribution of between 40 and 60 percent of adjusted net income starting with the 2026 financial year. ... MORE
Evonik Coating Additives introduces TEGO® Dispers 695, a novel hyperdispersant for radiation-curing inks and solventborne polyurethane inks. ... MORE
Evonik has entered a strategic partnership with InVitria, a leading developer of recombinant proteins and supplements, to supply animal component-free (ACF) recombinant human serum albumin to the global biopharmaceutical industry. ... MORE
Evonik and HosenCare officially announced the launch of a new China-focused innovation fund—Jinjiang Houxin—during the 8th China International Import Expo. The fund is jointly initiated with multiple partners to deepen local innovation collaboration and accelerate the commercialization of high-quality, sustainable technologies in China. ... MORE
In an environment of high uncertainty and weak demand, Evonik generated adjusted EBITDA of €448 million in the third quarter of 2025 ─ 22 percent below the robust prior-year results (Q3 2024: €577 million) and within the expected range of €420 million to €460 million as communicated on September 25. ... MORE